Lannett Company Inc
Change company Symbol lookup
Select an option...
LCI Lannett Company Inc
PRU Prudential Financial Inc
TACT TransAct Technologies Inc
TXN Texas Instruments Inc
T AT&T Inc
SXT Sensient Technologies Corp
SUPN Supernus Pharmaceuticals Inc
SIMO Silicon Motion Technology Corp
RFIL RF Industries Ltd
REED Reed's Inc
Go

Health Care : Pharmaceuticals | Small Cap ValueCompany profile

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Postmarket

Last Trade
Delayed
$0.00
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$8.80
Day's Change
0.31 (3.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
8.87
Day's Low
8.51
Volume
(Average)
Volume:
1,090,258

10-day average volume:
1,037,256
1,090,258

LCI's position in the Pharmaceuticals industry

Industry PeersLCIANIPAKRXASRT

Summary

Company ProfileLannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the...
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The...
Go to ANIP summary
Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as...
Go to AKRX summary
Assertio Therapeutics, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended...
Go to ASRT summary
52-Week Change

VS. INDUSTRY
61.17%
15.40%
-32.92%
-84.16%
Market Cap

VS. INDUSTRY
$342.4M
$709.6M
$461.7M
$56.8M
Beta

VS. INDUSTRY
2.1
2.0
1.8
1.8
Dividend Yield

VS. INDUSTRY
--
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
122.37x
43.82x
--
--
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$627.7M
$215.7M
$673.6M
$212.9M
Profit Margin

VS. INDUSTRY
0.52%
7.58%
-54.07%
-22.88%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
--
--
-5.25%
Revenue Growth (TTM)

VS. INDUSTRY
-8.32%
12.50%
-7.31%
-41.45%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2019. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.